Program
Panitumumab
Also written as “ABX-EGF”, “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” and “Panitumumab (ABX-EGF)”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.
Drug pagePanitumumab: every studyAll 196 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 351 open or running | phase 3since Jun 10, 2005 | Apr 25, 2002 | Sep 25, 2028phase 3 · NCT06252649 |
| Dr. Reddy's Laboratories | 10 open or running | phase 4since Nov 24, 2014 | Nov 24, 2014 | none ahead |
| R-Pharmits history only | 11 open or running | phase 1since Apr 14, 2026 | Apr 14, 2026 | none ahead |
Also a collaborator on its studies: Takeda and Immunex.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr. Reddy's Laboratories only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2014First study: phase 4 study in NeoplasmsFirst studyNCT02301962 · 58 enrolled · India
TargetBeta
“A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR)”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
The one study Dr. Reddy's Laboratories leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02301962Neoplasms · India | 4 | UNKNOWN | Jun 30, 2021 | 58 |
How it is read
Names in the registry
- “Panitumumab”, 29 entries
- “ABX-EGF”, 5 entries
- “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
- “Panitumumab (ABX-EGF)”, 2 entries
- “RPH-030”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 25 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colonic Neoplasms, 3 studies
- Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.